Drug intelligence / Profile preview

AD-II-GP

Development stage: Preclinical
Modality: Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies

Overview

AD-II-GP is a replication-deficient adenoviral vaccine designed to express a viral antigen linked to an invariant chain. It functions as a tumor vaccine candidate, primarily investigated in murine melanoma models. The drug aims to stimulate a robust and prolonged tumor-specific CD8 T cell response, which is crucial for achieving tumor regression and long-term survival. Its therapeutic effect is enhanced when combined with agonistic anti-CD40 monoclonal antibodies and anti-CTLA-4 monoclonal antibodies.

Other names: replication deficient adenovirus expressing a viral antigen linked to invariant chain

Targets

CD8A (CD8 alpha/beta Coreceptor)

Beyond the preview

Go deeper on AD-II-GP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-II-GP.

Explore the full profile